Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology · Maturity-Onset Diabetes of the Young

Treating MODY: Why You Might Not Need Insulin

At a Glance

The most important takeaway is that treating MODY depends on your specific genetic subtype. People with GCK-MODY generally require no medication, while those with HNF1A and HNF4A can often stop insulin and manage their blood sugar with oral sulfonylurea pills instead.

One of the most empowering aspects of a MODY diagnosis is the potential to change—or even stop—your current treatment. Because MODY is caused by a specific genetic “glitch,” we can often use precision medicine to target that exact problem [1][2]. For many, this means moving away from daily insulin injections in favor of oral tablets or no medication at all.

GCK-MODY (MODY2): Living Without Medication

If you have the GCK subtype, your body’s “glucose thermostat” is simply set higher than average [3][4].

  • The Treatment: Most people with GCK-MODY require no medication [2][5].
  • Why Stop? Research shows that even without treatment, people with GCK-MODY have a very low risk of the long-term heart, eye, or kidney complications usually associated with diabetes [5][6].
  • The Risk of Over-treating: Forcing your blood sugar lower with insulin or other drugs does not usually improve health outcomes in this subtype and can actually cause dangerous hypoglycemia (low blood sugar) as your body tries to fight to get back to its “natural” higher set point [2][7].

HNF1A and HNF4A: The Tablet Revolution

The most common forms of MODY (HNF1A and HNF4A) are often misdiagnosed as Type 1 diabetes because they occur in young people who eventually need help controlling their blood sugar [8][1].

  • Sulfonylurea Sensitivity: People with these subtypes are often remarkably sensitive to a class of oral medications called sulfonylureas (such as Gliclazide or Glipizide) [9][8].
  • The Transition: Because these pills stimulate your pancreas to release its own stored insulin, many patients can successfully transition off insulin and maintain excellent blood sugar control with just a small daily tablet [1][10].

Important Safety Warning: Because patients with HNF1A and HNF4A are exquisitely sensitive to sulfonylureas, the risk of severe hypoglycemia (dangerously low blood sugar) is very high when starting these medications [11]. Transitioning from insulin to oral pills must be done under close medical supervision. Your doctor will likely start you on a very low dose and carefully titrate it upwards while you monitor your blood sugar closely [11].

When is Insulin Necessary?

While many MODY patients can avoid insulin, there are specific situations where it remains the safest and most effective choice:

  • HNF1B-MODY (MODY5): Because this subtype often involves a pancreas that is physically smaller or underdeveloped, the body simply cannot produce enough insulin on its own [12][13]. Most people with this subtype will eventually need insulin therapy [14].
  • Long-standing Disease: In some cases of HNF1A or HNF4A, the pancreas’s ability to produce insulin can slowly decline over many years. If oral tablets are no longer enough to keep blood sugar in a healthy range, insulin may be added back to the treatment plan [15].
  • Pregnancy: Managing MODY during pregnancy is complex. In GCK-MODY, treatment depends on whether the baby has inherited the mutation [16]. In other types, doctors may switch patients to insulin temporarily to ensure the most precise control for the baby’s health [17].

Other Emerging Options

For patients who cannot take sulfonylureas or who need additional help, newer classes of medications are being used with success:

  • SGLT2 Inhibitors: These help the kidneys flush extra sugar out through urine [18][19].
  • GLP-1 Receptor Agonists: These injectable (non-insulin) medications can help the pancreas release insulin more effectively and may offer heart-health benefits [20][21].
Subtype Typical First-Line Treatment Why?
GCK (MODY2) Diet and monitoring only Blood sugar is stable and low-risk [2]
HNF1A (MODY3) Low-dose Sulfonylureas High sensitivity to oral pills [9]
HNF4A (MODY1) Low-dose Sulfonylureas High sensitivity to oral pills [1]
HNF1B (MODY5) Insulin Pancreas is often underdeveloped [12]

Previous: Testing for MODY | Return to Home | Next: MODY and Pregnancy

Common questions in this guide

Can I stop taking insulin if I have MODY?
Many people with specific types of MODY, such as HNF1A or HNF4A, can safely transition from insulin to oral medications called sulfonylureas. However, this transition must be done under strict medical supervision to avoid dangerously low blood sugar.
Do I need medication for GCK-MODY (MODY2)?
Most people with GCK-MODY do not require any diabetes medication. In this specific subtype, your body's baseline blood sugar is naturally set higher, but the risk for long-term diabetes complications remains very low. Using insulin can actually cause dangerous low blood sugar.
What are sulfonylureas and how do they treat MODY?
Sulfonylureas are a class of oral diabetes pills that stimulate your pancreas to release its own stored insulin. People with HNF1A and HNF4A MODY are highly sensitive to these medications, making them an excellent alternative to daily insulin injections.
Will I ever need insulin again if I have MODY?
It depends on your situation and subtype. People with HNF1B-MODY typically require insulin because their pancreas is underdeveloped. Others might temporarily need insulin during pregnancy, or later in life if their pancreas's ability to produce insulin naturally declines.
What are the risks of treating GCK-MODY with insulin?
If you have GCK-MODY, using insulin to lower your blood sugar can be dangerous. It forces your blood sugar lower than your body's natural set point, which can cause severe hypoglycemia (low blood sugar) without improving your long-term health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific MODY subtype, can we discuss a plan to transition from insulin to an oral sulfonylurea medication safely?
  2. 2.Given the high risk of low blood sugar during the transition, how exactly will we titrate the sulfonylurea dose?
  3. 3.If I have GCK-MODY, what are the risks of continuing my current diabetes medication if my blood sugar is already stable?
  4. 4.Are there other oral options, like SGLT2 inhibitors or GLP-1 agonists, that might be appropriate for my subtype?
  5. 5.If my insulin production declines over time, what symptoms or lab changes should I look for that indicate I need to restart insulin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.

    Campos Franco P, Santos de Santana L, Dantas Costa-Riquetto A, et al.

    Diabetes research and clinical practice 2022; (187()):109875 doi:10.1016/j.diabres.2022.109875.

    PMID: 35472491
  2. 2

    Genetic causes and treatment of neonatal diabetes and early childhood diabetes.

    Barbetti F, D'Annunzio G

    Best practice & research. Clinical endocrinology & metabolism 2018; (32(4)):575-591 doi:10.1016/j.beem.2018.06.008.

    PMID: 30086875
  3. 3

    Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy.

    Tatsi EB, Kanaka-Gantenbein C, Scorilas A, et al.

    Pediatric diabetes 2020; (21(1)):28-39 doi:10.1111/pedi.12931.

    PMID: 31604004
  4. 4

    Glucokinase Variant Proteins Are Resistant to Fasting-Induced Uridine Diphosphate Glucose-Dependent Degradation in Maturity-Onset Diabetes of the Young Type 2 Patients.

    Cho J, Horikawa Y, Oiwa Y, et al.

    International journal of molecular sciences 2023; (24(21)) doi:10.3390/ijms242115842.

    PMID: 37958824
  5. 5

    Glucokinase-maturity onset diabetes mellitus in the young suggested by factory-calibrated glucose monitoring data: a case report.

    Nomura N, Iizuka K, Goshima E, et al.

    Endocrine journal 2022; (69(4)):473-477 doi:10.1507/endocrj.EJ21-0526.

    PMID: 34803122
  6. 6

    Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY.

    Wang X, Lam SM, Cao M, et al.

    Redox biology 2021; (40()):101855 doi:10.1016/j.redox.2021.101855.

    PMID: 33450726
  7. 7

    Heterozygous lys169Glu mutation of glucokinase gene in a Chinese family having glucokinase-maturity-onset diabetes of the young (GCK-MODY).

    Zhou W, Chen M, Zhou H, Zhang Z

    Journal of postgraduate medicine 2019; (65(4)):241-243 doi:10.4103/jpgm.JPGM_166_19.

    PMID: 31571622
  8. 8

    A novel HNF4A mutation identified in a child with maturity onset diabetes of the young.

    Zhu MQ, Dai YL, Chen XF, et al.

    World journal of pediatrics : WJP 2022; (18(11)):778-780 doi:10.1007/s12519-022-00512-w.

    PMID: 35118593
  9. 9

    Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report.

    Xu Q, Kan CX, Hou NN, Sun XD

    World journal of clinical cases 2022; (10(6)):1909-1913 doi:10.12998/wjcc.v10.i6.1909.

    PMID: 35317157
  10. 10

    [Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy].

    Kaser S, Resl M

    Wiener klinische Wochenschrift 2016; (128 Suppl 2()):S204-7 doi:10.1007/s00508-015-0938-9.

    PMID: 27052244
  11. 11

    Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young.

    Pandya S, Khairati R, Mann J, et al.

    European journal of case reports in internal medicine 2025; (12(12)):005892 doi:10.12890/2025_005892.

    PMID: 41377795
  12. 12

    Case Report: A case of HNF1B mutation patient with first presentation of diabetic ketosis.

    Ge S, Yang M, Gong W, et al.

    Frontiers in endocrinology 2022; (13()):917819 doi:10.3389/fendo.2022.917819.

    PMID: 35992134
  13. 13

    Insights into the etiology and physiopathology of MODY5/HNF1B pancreatic phenotype with a mouse model of the human disease.

    Quilichini E, Fabre M, Nord C, et al.

    The Journal of pathology 2021; (254(1)):31-45 doi:10.1002/path.5629.

    PMID: 33527355
  14. 14

    Maturity-onset diabetes of the young type 5 a MULTISYSTEMIC disease: a CASE report of a novel mutation in the HNF1B gene and literature review.

    Mateus JC, Rivera C, O'Meara M, et al.

    Clinical diabetes and endocrinology 2020; (6()):16 doi:10.1186/s40842-020-00103-6.

    PMID: 32864159
  15. 15

    Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.

    Warncke K, Kummer S, Raile K, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(3)):845-855 doi:10.1210/jc.2018-01696.

    PMID: 30535056
  16. 16

    Pregnancy and Neonatal Outcomes in Maturity-Onset Diabetes of the Young: A Systematic Review.

    Ługowski F, Babińska J, Makowska K, et al.

    International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26136057.

    PMID: 40649834
  17. 17

    Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.

    Shepherd M, Brook AJ, Chakera AJ, Hattersley AT

    Diabetic medicine : a journal of the British Diabetic Association 2017; (34(10)):1332-1339 doi:10.1111/dme.13388.

    PMID: 28556992
  18. 18

    Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.

    Maagensen H, Jensen JS, Høyerup SO, et al.

    Diabetes care 2025; (48(9)):1536-1544 doi:10.2337/dc25-0737.

    PMID: 40608360
  19. 19

    Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review.

    Bombonato M, Beccuti G, Benso A, et al.

    Hormones (Athens, Greece) 2025; (24(2)):495-498 doi:10.1007/s42000-025-00632-8.

    PMID: 39903441
  20. 20

    Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy.

    Fantasia KL, Steenkamp DW

    Journal of the Endocrine Society 2019; (3(12)):2286-2289 doi:10.1210/js.2019-00278.

    PMID: 31737858
  21. 21

    Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular Disease.

    Yang C, Ji L, Han X

    The Journal of clinical endocrinology and metabolism 2025; (110(2)):592-600 doi:10.1210/clinem/dgae602.

    PMID: 39210612

This page provides educational information about MODY treatment options. Always consult your endocrinologist before making any changes to your insulin or diabetes medication regimen, as improper changes can cause severe hypoglycemia.

Get notified when new evidence is published on MODY.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.